Pathogenesis and treatment of mature T cell tumors

Share This Post

Mature T-cell tumors, such as non-Hodgkin T-cell lymphoma, are highly invasive and drug-resistant, and patients often have a poor prognosis. Recently, “Nature” series of two articles published a new interpretation of the pathogenesis of non-Hodgkin’s T-cell lymphoma, thus providing a new direction for the effective development of new therapies for this type of malignant lymphoma.

In the first study, the Wartewig team used the fusion protein ITK-SYK to construct a transgenic mouse model of late-onset T-cell lymphoma (Nature. Doi: 10.1038 / nature24649), and found that the single or double copy of the PDCD1 gene encoding the PD1 protein was deleted. T cell lymphoma undergoes rapid malignant transformation and accelerates the death of the mouse model. In addition, the application of PD1 or PD-L1 inhibitors can produce similar effects. The related mechanism is that PD1 up-regulates PTEN expression and inhibits the tumor malignant proliferation pathway PI3K.

In another article, Maciocia et al. Applied chimeric antigen receptor T cell immunotherapy (CAR-T) therapy (Nat Med. Doi: 10.1038 / nm.4444) to construct CAR-T cells that specifically target TRBC1 but not TRBC2 To treat TRBC1-positive T-cell carcinoma. While killing tumor cells, leaving enough T cells to fight infection. The clinical trial of this method will be officially launched in 2018.

Nature senior editor Megan Cully said that the above-mentioned important findings provide a new treatment strategy for the treatment of mature T-cell malignancies and warn that these tumors are not suitable for treatment with PD1 or PDL1 inhibitors. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy